Logo
D

DefiniGEN

29 employees

Definigen provides human cells to the drug discovery sector for use in lead optimization and toxicity programs.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Pharmaceutical
Toxicity testing
Induced Pluripotent Stem Cells (iPSC)
Inherited Metabolic Diseases (IMD)
Drug Discovery
Hepatocytes
Health Care
Disease Modelling
Pancreatic Cells

Date founded

2012

Funding rounds raised

Total raised

$4.4M

from 8 investors over 8 rounds

D

DefiniGEN raised $4.4M on November 19, 2020

Investors: 24Haymarket

D

DefiniGEN raised $899K on November 1, 2018

Investors: 24Haymarket

D

DefiniGEN raised $2.2M on May 23, 2016

Investors: Cambridge Enterprise, Parkwalk Advisors, Cambridge Angels and 24Haymarket

D

DefiniGEN raised $3.9M on June 2, 2014

Investors: Cambridge Enterprise and 24Haymarket

FAQ